This meta‐analysis is the first to evaluate the efficacy and safety of once‐weekly basal insulins in the treatment of adults with type 1 diabetes, showing a similar glucose‐lowering effect with increased hypoglycaemia occurrence compared to once‐daily compounds. This evidence concerns the gene INS and type 1 diabetes mellitus.